Prange Pharma Acquires Site in Italy from MSD

Prange Pharma is taking over a production site from MSD Animal Health in Aprilia, Italy. A new center for contract manufacturing in the field of animal health products is to be established there. The formal transfer of ownership will be completed in the coming months.

Upon completion of the sale, the site will operate under the name Aprilia Animal Health and will be positioned as a specialized contract manufacturing center for animal health products. The site's portfolio includes both sterile and non-sterile manufacturing and filling, with capacity for beta-lactam antibiotics as well as specialized product categories such as ectoparasiticides.

Prange Pharma is currently negotiating the terms of a long-term supply partnership with MSD, which is expected to be signed upon completion of the transaction.

Prange Pharma is part of the owner-managed Prange Group, a renowned German family-owned company based in Plettenberg in North Rhine-Westphalia. The pharmaceutical business is managed operationally from the Leipzig site.

Through Prange Pharma, the Group has been offering contract development and manufacturing organization (CDMO) services at several locations since 1996. In addition to the CDMO business, Prange Pharma supports a diverse portfolio of human and veterinary pharmaceuticals - including OTC and prescription medicines, medical devices, cosmetics, feed additives and antiparasitics.

Otto Prange, owner of the Prange Group, commented: "This acquisition is a strategic step to strengthen our presence in Europe and expand our expertise in the manufacturing of animal health products. We are determined to invest in the site, preserve jobs and develop new growth opportunities together with our partners. Aprilia Animal Health will play a central role in our long-term strategy."

Sebastian Heckerodt, Managing Director of Prange Pharma GmbH, added: "Our goal is to further develop Aprilia Animal Health into a center of excellence for contract manufacturing, while ensuring the seamless continuation of deliveries to P4SD and creating added value for new customers."

Prange Pharma facility
Since 1996, the activities relating to pharmaceutical products and services of the family-run Prange group of companies have been bundled under the umbrella of Prange Pharma.
© Prange-Gruppe

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read